The competitive NMDA receptor antagonist, CGP 39551, inhibits ethanol withdrawal seizures.
Liljequist
S
S
Department of Drug Dependence Research, Karolinska Institute, Stockholm, Sweden.
D015763:2-Amino-5-phosphonovalerate / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D004032:Diet; D016291:Dizocilpine Maleate / Q000378:metabolism; D000431:Ethanol / Q000494:pharmacology*; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors*; D012640:Seizures / Q000517:prevention & control; D013375:Substance Withdrawal Syndrome / Q000517:prevention & control*
D016194:Receptors, N-Methyl-D-Aspartate; C064540:CGP 39551; D000431:Ethanol; D016291:Dizocilpine Maleate; D015763:2-Amino-5-phosphonovalerate